30 years. 30 patents. 250+ life-science companies.
Your science can earn the grant. Your commercialization plan can lose it.
For physician founders writing SBIR/STTR applications: a grant-ready commercialization plan that reviewers score, investors trust, and your company can actually run on.
The problem
You’re a clinician, not a commercialization strategist.
You can defend the science in your sleep. But the commercialization plan, market size, reimbursement pathway, competitive differentiation, financial projections, is a different discipline entirely, and it’s the section where strong applications quietly lose points and investors go quiet.
The commercialization plan is where funding is won or lost. It shouldn’t be the part you write last, alone, the night before the deadline.
Why it matters
Reviewers score it. Investors demand it. Most founders underbuild it.
Reviewers score it
NIH reviewers evaluate the commercialization plan as its own criterion. A weak one drags down an otherwise fundable score, and re-submission costs you months.
Investors demand it
No investor or strategic partner moves without a credible market, a reimbursement path, and financials that hold up under scrutiny.
DIY plans miss the mark
Written alone, plans miss what reviewers and investors look for: defensible market size, a clear reimbursement pathway, real differentiation, and projections that add up.
Why now
The bar on commercialization just went up.
The 2026 SBIR/STTR reauthorization, now signed into law, strengthened the program’s focus on commercialization, expanding support for market research, IP strategy, regulatory planning, and manufacturing, and adding new awards to push technologies toward market. Reviewers are weighing how you’ll actually reach patients and revenue more heavily than ever.
In a stack of strong science, a rigorous commercialization plan is how you stand out from the other applications.
What you get
A grant-ready commercialization plan, built with you.
Market & value
Target-market attractiveness, features-to-need mapping, competitive differentiation, and a value proposition that lands with reviewers and buyers alike.
Reimbursement, regulatory & clinical
The coverage, regulatory, and clinical-evidence story that payers, reviewers, and partners need to see, integrated and aligned with your application.
Financials, milestones & timeline
Financial projections, budget, and milestones built to slot straight into your grant application, and to survive an investor’s due diligence.
You get a finalized commercialization plan you can submit with your grant, and reuse as the backbone for fundraising, sales, and partnerships.
Why founders choose m.zoro
Experts who tell you the truth.
Experts, not generalists
Senior commercialization expertise, not a junior analyst with a template.
If you don’t need it, we don’t sell it
We scope to what your application and stage actually require, nothing you don’t.
Everything’s connected
Commercialization fails at the intersections of regulatory, reimbursement, market, and funding, so we build the plan as one connected whole, not siloed sections.
Hard truths, early
We tell you what reviewers and investors will push on while there’s still time to fix it.
Proof
Plans that move the score.
$3.4M in NIH funding secured on a client’s grant resubmission.
“Through our work with Michele and her team to improve our commercialization plan, we received a fundable score of 20 (reduced from 41) on our NIH Commercialization Readiness Pilot Program grant application.”
M.C., Founder & CEO, Lymph/Axis
“The TABA Needs Assessment really helped us write our NIH Phase II grant. The whole process really paid off for us.”
C.E., CRM Medical Device
“Michele’s team efficiently gathered details on our company and translated the data into highly valuable actionable intelligence in a concise format. Highly recommended!”
B.B., Founder & CEO, Quench Medical
One plan, many uses
Write it once. Use it everywhere.
Non-dilutive funding
SBIR/STTR and other grant applications, where the commercialization plan is scored.
Dilutive funding
Angel, seed, and strategic investors who need a credible market and financial story.
Roadmap to commercialization
The plan your team executes against, from clinical proof to first revenue.
Marketing and sales
The market, value proposition, and positioning your go-to-market runs on.
How it works
Collaborative, and built to your deadline.
1. Kickoff and data gathering. We start from what you have: your draft, research strategy, pitch deck, budget, and clinical data.
2. Assessment and gap-finding. We map what’s strong, what’s missing, and what reviewers and investors will push on.
3. Straw-man drafts. We draft the hard sections and pull the specifics from you, instead of handing you a blank template.
4. Review and refine. We work through drafts together until the plan is tight, aligned to your application, and defensible.
5. Finalized plan. A submission-ready commercialization plan, delivered on the timeline your deadline requires.
You built the practice. We’ll build the company.
Every engagement is scoped to your application and your timeline. Have a deadline coming? Let’s talk before it’s too tight.
m.zoro Consulting | mzoro.com | 1-855-FRPA-FIX (1-855-377-2349) | woman-majority owned business